Stocks Health care ANGO
NASDAQ · Health careAngiodynamics Inc (ANGO)
Angiodynamics Inc brought in $325.4M of revenue over the twelve months to August 31, 2026, up 8.2% from a year earlier. It posted a net loss of $32.9M. Operating cash flow minus capital spending left $508K of free cash flow in fiscal 2026. At August 31, 2026 it held $34M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on October 8, 2026.
Key facts about Angiodynamics Inc
- Net worth
- Angiodynamics Inc has a market value (market cap) of $498.9M at the latest share price, and shareholders' equity of $164M on its balance sheet at August 31, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2026 revenue was $320.2M (+9.5% year on year), with a net loss of $36.7M. Over the 12 months to August 31, 2026: revenue $325.4M, net loss $32.9M.
- Cash flow
- In fiscal 2026 operations brought in $3.1M of cash; after $2.6M of capital spending, free cash flow was $508K.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on October 8, 2026 and covers the period to August 31, 2026. Open on SEC EDGAR
- Next earnings report
- Angiodynamics Inc's next report is expected around January 5, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Angiodynamics Inc does
Angiodynamics Inc is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker ANGO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2026 | $320.2M | -$36.7M | -$0.88 | $508K |
| 2025 | $292.5M | -$34M | -$0.83 | -$14.6M |
| 2024 | $303.9M | -$184.4M | -$4.59 | -$30.7M |
| 2023 | $338.8M | -$52.4M | -$1.33 | -$3.7M |
| 2022 | $316.2M | -$26.5M | -$0.68 | -$11.5M |
| 2021 | $291M | -$31.5M | -$0.82 | $18.9M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where ANGO ranks in Health care
Latest SEC filings
What Angiodynamics Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 8, 2026Quarterly report10-Q · period to August 31, 2026AngioDynamics grew revenue and expanded gross margins in the first quarter of fiscal 2027 while reducing its net loss.Revenue rose 6.9% to $80.9M versus the same quarter last year; diluted EPS -$0.17 versus -$0.26.
- October 8, 2026Additional proxy material DEFA14A
- October 8, 2026Proxy statement DEF 14A
- October 8, 2026Quarterly results8-KAngioDynamics reported first quarter net sales of $80.9 million and narrowed its net loss amid double-digit Med Tech growth.
- October 8, 2026Executive or director change8-KAngioDynamics appointed Eric Honroth as President and Chief Executive Officer, succeeding retiring CEO James C. Clemmer effective November 2, 2026.
- September 29, 2026Annual report (amended) 10-K/A · period to May 31, 2026Revenue rose 9.5% to $320.2M versus the prior year; diluted EPS -$0.88 versus -$0.83.
- September 29, 2026Annual report (amended) 10-K/A · period to May 31, 2026Revenue rose 9.5% to $320.2M versus the prior year; diluted EPS -$0.88 versus -$0.83.
- July 14, 2026Annual report 10-K · period to May 31, 2026Revenue rose 9.5% to $320.2M versus the prior year; diluted EPS -$0.88 versus -$0.83.
- July 14, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
What is ANGO worth? A DCF from its reported cash flow
Insider trades
What the people running Angiodynamics Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $310.7K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 2, 2026 | Honroth EricPresident and CEO, Director | Received as pay | 62,928 | - |
| November 2, 2026 | Honroth EricPresident and CEO, Director | Received as pay | 38,265 | - |
| October 29, 2026 | Trowbridge Stephen AEVP and CFO | Sold | 23,615 | $289.8K |
| October 28, 2026 | Trowbridge Stephen AEVP and CFO | Sold | 1,720 | $20.9K |
| July 30, 2026 | Nighan Warren JRSVP Quality and Regulatory | Sold | 23,370 | $344K |
| July 22, 2026 | Campbell Chad ThomasSVP/GM, Vascular Access | Exercised options | 6,466 | - |
| July 22, 2026 | Campbell Chad ThomasSVP/GM, Vascular Access | Shares withheld for tax | 2,330 | $32.2K |
| July 22, 2026 | Clemmer James CPresident and CEO, Director | Exercised options | 52,358 | - |
Who owns ANGO
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Point72 Asset Management, L.P.13G, passive with 2 related filers | 7.7% | May 15, 2026 |
| Systematic Financial Management LP13G, passive | 6.1% | February 10, 2026 |
| Kevin Kotler13G, passive | 5.9% | February 9, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 162 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 3,803,232 | +117,328 |
| Point72 Asset Management, L.P. | 3,062,517 | -119,312 |
| Systematic Financial Management LP | 2,640,214 | +186,513 |
| Armistice Capital, LLC | 2,198,000 | +329,000 |
| Royce & Associates LP | 1,969,835 | +440,884 |
| Broadfin Holdings LLC | 1,818,533 | -250,800 |
| Vanguard Capital Management LLC | 1,694,716 | -32,104 |
| Weber Capital Management LLC | 1,356,602 | -16,547 |
| Nuveen, LLC | 1,199,358 | -16,807 |
| Geode Capital Management, LLC | 1,020,658 | +35,235 |
| Dimensional Fund Advisors LP | 969,497 | +20,682 |
| State Street Corp | 958,167 | -375,691 |
| Segall Bryant & Hamill, LLC | 926,711 | -39,254 |
| Bastion Asset Management Inc. | 923,270 | -389,732 |
| Pier Capital, LLC | 806,678 | +9,982 |
| Millennium Management LLC | 783,125 | +138,448 |
| Renaissance Technologies LLC | 733,883 | -69,400 |
| Arrowstreet Capital, Limited Partnership | 692,534 | -65,916 |
| Paradigm Capital Management Inc | 671,200 | -47,000 |
| Aqr Capital Management LLC | 589,157 | +337,643 |
Insiders
14 insiders reported holding 2,423,402 shares in total, about $29.3M at the last price.
| Holder | Shares |
|---|---|
| Clemmer James CPresident and CEO, Director | 862,448 |
| Trowbridge Stephen AEVP and CFO | 280,461 |
| Donnelly Howard WDirector | 178,938 |
| Johnson WesleyDirector | 155,425 |
| Reed Jan SternDirector | 116,921 |
| Auen Eileen O'SheaDirector | 116,605 |
| Campbell Chad ThomasSVP/GM, Vascular Access | 108,676 |
| Licitra Karen ADirector | 102,322 |
| Honroth EricPresident and CEO, Director | 101,193 |
| Tarnoff Michael EDirector | 95,265 |
Questions about ANGO
What does Angiodynamics Inc do?
Angiodynamics Inc is a company in the Health care sector, listed on NASDAQ as ANGO. Its shares trade on NASDAQ under the ticker ANGO.
What is Angiodynamics Inc's net worth?
Angiodynamics Inc has a market value (market cap) of $498.9M at the latest share price, and shareholders' equity of $164M on its balance sheet at August 31, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Angiodynamics Inc profitable?
No. Over the twelve months to August 31, 2026 it reported a net loss of $32.9M on revenue of $325.4M.
How much revenue does Angiodynamics Inc make?
Over the twelve months to August 31, 2026 Angiodynamics Inc reported revenue of $325.4M. That is 8.2% more than a year earlier.
When did Angiodynamics Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on October 8, 2026. It covers the period to August 31, 2026. Its newest filing of any kind is the insider trade from November 4, 2026.
When is Angiodynamics Inc's next earnings report?
Angiodynamics Inc's next report is expected around January 5, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ANGO with
Follow ANGO
Get an email when Angiodynamics Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Angiodynamics Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.